Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
SECAUCUS, N.J., July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.
Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. The test is the first blood-based IVD test cleared by the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. It is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline.
Through its AD-Detect™ portfolio, Quest provides a suite of advanced lab-developed blood tests regulated under CLIA for assessing patients with cognitive impairment for Alzheimer's disease. The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings.
"Our goal is to advance access to quality and innovative blood-based tests for Alzheimer's disease. Adding the Fujirebio test to our existing blood-based tests provides the many physicians we serve with another powerful option for assessing patients for Alzheimer's disease," said Kathleen Valentine, Vice President and General Manager, Neurology, Quest Diagnostics. "Blood-based testing can be less invasive and more convenient than traditional test methods. We are excited to leverage our expansive network of patient service centers to broaden access to the Fujirebio innovation to help more at-risk individuals gain access to the insights they need sooner."
In a clinical study population of 499 patients, which closely mirrors US demographics, and when applying a dual cut point, the FDA-cleared test demonstrated a positive predictive value (PPV) of 92% and a negative predictive value (NPV) of 97%, with 20% of patients uncertain to have amyloid pathology, thus requiring further testing.
Quest will showcase its complete line up of Alzheimer's and other neurological test innovations at this year's Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31.
"As brain health and Alzheimer's disease interventions continue to evolve, diagnosing patients earlier, when interventions can be most effective, is critical," said Michael Racke, MD, a board-certified neurologist and Medical Director of Neurology, Quest Diagnostics. "We are constantly looking for ways to help physicians and patients make the most informed decisions, and this new addition to our test menu will aid that goal."
While amyloid PET imaging and cerebral spinal fluid testing are established methods for aiding the diagnosis of Alzheimer's disease, they are significantly more expensive, invasive and specialist-dependent than blood-based tests. With a physician's order, patients can conveniently provide a blood draw for testing for the Fujirebio test and any of the AD-Detect™ tests through Quest's network of patient sites. Quest maintains approximately 8,000 patient access points, including an extensive patient service center network of approximately 2,000 locations in the U.S., as well as phlebotomists in physician offices and mobile phlebotomy services. Specimens will be transported for testing to Quest's state-of-the-art laboratory in San Juan Capistrano, California.
Nearly 7 million Americans have Alzheimer's, the most prevalent dementia, a number projected to reach 14 million by 2060. Approximately 12-18% of adults over the age of sixty are living with mild cognitive impairment, a potential sign of AD. Seventy-seven percent of physicians say new therapies will transform Alzheimer's into a chronic, manageable disease, and 94% of physicians say blood tests would be more cost effective for the healthcare system compared to more invasive methods of detection (e.g., lumbar puncture, imaging studies) according to a special report from Quest.
Quest is committed to developing and offering innovative advanced diagnostics to aid in evaluating Alzheimer's disease and other brain diseases. For more information, visit www.QuestForTheCure.com.
About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-offer-fda-cleared-fujirebio-blood-test-for-alzheimers-disease-302500634.html
SOURCE Quest Diagnostics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
22 minutes ago
- Wall Street Journal
Bill Gates: U.S. Aid for Global Health Is Saving Lives
When I was running Microsoft, we sometimes had to make difficult changes to our business. One key to our long-term success was that every time we decided to pivot, we studied the evidence to pinpoint what wasn't working and needed to shift—but also what was working and needed to be preserved. The Senate is about to consider a rescission bill that would eliminate more than $8 billion in lifesaving foreign aid, including nearly $1 billion in direct aid for global health programs, on top of the billions in such aid that has already been canceled. I'm alarmed at how a bid to eliminate inefficiencies in the U.S. budget—an important task—has put us on the verge of cutting funds for almost every single effective lifesaving aid program and, with it, our country's proud history of helping others less fortunate than ourselves. The proposal to cut this aid passed the House last month, and the Senate is expected to vote this week. Before senators decide to cut funds for global health programs, they should understand what this spending is, what it isn't, and all the U.S. has gained from it. I have now been working in global health for almost as long as I worked at Microsoft. The Gates Foundation has spent more than $100 billion, and I am as committed to excellence in this work as I was to Microsoft's. In global health, that means saving as many people's lives as possible for every dollar we spend on medicines or vaccines. That requires tracking and analyzing results closely, asking tough questions of my team, and seeing the work in action. I've been following the political debate over aid in the U.S., and there are three facts about health aid that keep getting lost in the back and forth.
Bloomberg
33 minutes ago
- Bloomberg
RFK Jr. Vows to Halt ‘Attack' on Fats in Whole Milk and Cheese
Health and Human Services Secretary Robert F. Kennedy Jr. and other top public health officials said Monday that saturated fats, long blamed for increased risk of heart disease, have been unfairly demonized by the medical community, indicating a pivot on government health guidelines is taking shape. 'There's a tremendous amount of emerging science that talks about the need for more protein in our diets, more fats in our diets,' Kennedy said Monday at a US Department of Agriculture event.
Fox News
34 minutes ago
- Fox News
Men face double dementia risk if they have a hidden genetic mutation
A hidden genetic mutation could predict a man's likelihood of developing dementia. That's according to an Australian study led by Monash and Curtin Universities, which analyzed the medical data of thousands of Australians and Americans. Men who had a certain variant in the haemochromatosis (HFE) gene — which regulates iron levels in the body — were found to be at a higher risk of dementia, the researchers found. Previously healthy men over age 70 who have two copies of the variant, which is known as H63D, are at least twice — or up to four times — as likely to develop dementia. Having just one copy did not appear to elevate the risk. One in 36 men carry two copies of the mutation; one in three have just a single copy. "It is only men who have two copies of the variant that are at risk," study co-author Professor John Olynyk from the Curtin Medical School told Fox News Digital. "Women are not affected by the abnormality – we do not know why that is at the current point in time." The study, which was published in the journal Neurology, used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, which gathered health and aging data for 19,114 healthy older adults. Those who have the genetic variant can't change it, but it's possible that the "brain pathways" it affects could be treated, Olynyk noted. "The HFE gene is routinely tested for in most Western countries … when assessing people for haemochromatosis, a disorder that causes the body to absorb too much iron," the doctor said. "Our findings suggest that perhaps this testing could be offered to men more broadly." Despite the fact that the HFE gene is responsible for controlling iron levels, the team found no direct link between iron and dementia risk. "Our findings suggest that perhaps this testing could be offered to men more broadly." "This points to other mechanisms at play, possibly involving the increased risk of brain injury from inflammation and cell damage in the body," Olynyk added. More research is needed to determine why the heightened risk wasn't seen in women. "Understanding why men with the double H63D variant are at higher risk could pave the way for more personalized approaches to prevention and treatment," added co-author Professor Paul Lacaze from Monash University in a press release. The main limitation of the study, according to Olynyk, was that the study population was largely composed of Australians. "Whether other populations exhibit the same effects is unclear," he told Fox News Digital. "Our work should be repeated in different countries to assess this." "Further research will be undertaken to try and determine the likely mechanism by which this anomaly causes dementia and what more we can do to reduce the impact of it." Beyond this specific mutation, many other genetic and environmental factors can contribute to dementia risk, Olynyk noted. "While genetic risk factors cannot be changed, the mechanisms by which these genetic abnormalities and environmental factors cause disease may well be modifiable to some extent, through adopting a healthy lifestyle and being proactive about maintaining an overall good state of health," he said. To reduce risk, the researchers recommend adopting a healthy lifestyle that includes exercising regularly, eating a nutritious diet, minimizing alcohol intake, remaining mentally active, and seeing a doctor to address any medical problem known to increase the likelihood of dementia. For more Health articles, visit The University of Melbourne, The Royal Children's Hospital, Murdoch Children's Research Institute and Fiona Stanley Hospital also contributed to the study.
